Publications

Chemogenomic landscape of RUNX1-mutated AML reveals importance of RUNX1 allele dosage in genetics and glucocorticoid sensitivity.Simon L, Lavallée VP, Bordeleau ME, Krosl J, Baccelli I, Boucher G, Lehnertz B, Chagraoui J, MacRae T, Ruel R, Chantigny YA, Lemieux S, Marinier A, Hébert J, Sauvageau GClin. Cancer Res. 2017-08-30.

MiSTIC, an integrated platform for the analysis of heterogeneity in large tumour transcriptome datasets.Lemieux S, Sargeant T, Laperrière D, Ismail H, Boucher G, Rozendaal M, Lavallée VP, Ashton-Beaucage D, Wilhelm B, Hébert J, Hilton DJ, Mader S, Sauvageau GNucleic Acids Res. 2017-07-27;45(13):e122.

A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens.Baccelli I, Krosl J, Boucher G, Boivin I, Lavallée VP, Hébert J, Lemieux S, Marinier A, Sauvageau GBlood Cancer J 2017-02-17;7(2):e529.

MHC class I-associated peptides derive from selective regions of the human genome.Pearson H, Daouda T, Granados DP, Durette C, Bonneil E, Courcelles M, Rodenbrock A, Laverdure JP, Côté C, Mader S, Lemieux S, Thibault P, Perreault CJ. Clin. Invest. 2016-12-01;126(12):4690-4701.

Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancers.Rouette A, Trofimov A, Haberl D, Boucher G, Lavallée VP, D'Angelo G, Hébert J, Sauvageau G, Lemieux S, Perreault CSci Rep 2016-09-23;6:34019.

Identification of MYC mutations in acute myeloid leukemias with NUP98-NSD1 translocations.Lavallée VP, Lemieux S, Boucher G, Gendron P, Boivin I, Girard S, Hébert J, Sauvageau GLeukemia 2016-07-01;30(7):1621-4.

Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.Lavallée VP, Krosl J, Lemieux S, Boucher G, Gendron P, Pabst C, Boivin I, Marinier A, Guidos CJ, Meloche S, Hébert J, Sauvageau GBlood 2016-06-16;127(24):3054-61.

Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets.Maiga A, Lemieux S, Pabst C, Lavallée VP, Bouvier M, Sauvageau G, Hébert JBlood Cancer J 2016-06-03;6(6):e431.

Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers.Granados DP, Rodenbrock A, Laverdure JP, Côté C, Caron-Lizotte O, Carli C, Pearson H, Janelle V, Durette C, Bonneil E, Roy DC, Delisle JS, Lemieux S, Thibault P, Perreault CLeukemia 2016-06-01;30(6):1344-54.

RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature.Lavallée VP, Lemieux S, Boucher G, Gendron P, Boivin I, Armstrong RN, Sauvageau G, Hébert JBlood 2016-05-19;127(20):2498-501.

Page précédente   |   Page suivante

Suivez l'IRIC

Logo UdeM